ClinicalTrials.gg

Program

budoprutug

Also written as “Budoprutug” and “VB119”.

Its studies are mostly in Glomerulonephritis, Membranous · Lupus Erythematosus, Systemic · Purpura, Thrombocytopenic, Idiopathic · Nephrosis, Lipoid, led by 2 companies.

Furthest: phase 2, since Jun 20, 20258 company-led studies, 4 open or runningNext primary completion: Apr 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Climb Bio54 open or runningphase 2since Jun 20, 2025May 6, 2025Apr 2027phase 1 · NCT07011043
Tenet Medicines30 open or runningphase 2since Nov 23, 2020Nov 23, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 23, 2020First study: phase 2 study in Glomerulonephritis, MembranousNew to Tenet MedicinesTenet Medicines · NCT04652570 · 6 enrolled · United States
  2. Jun 7, 2022Phase 2 study in Nephrosis, LipoidTenet Medicines · NCT05441826 · 1 enrolled · United States
  3. Aug 19, 2024Phase 2 study in Lupus Erythematosus, SystemicTenet Medicines · NCT06570434
  4. May 6, 2025Climb Bio's first study: phase 1 study in Lupus Erythematosus, SystemicNew to Climb BioClimb Bio · NCT07011043 · 30 planned · United States, Bulgaria, Georgia and more
  5. Jun 20, 2025Phase 2 study in Purpura, Thrombocytopenic, IdiopathicClimb Bio · NCT07043946 · 24 planned · Bulgaria, Greece, Serbia and more
  6. Jul 21, 2025Early phase 1 study in Healthy VolunteersClimb Bio · NCT07090655 · 30 enrolled · Australia
  7. Jul 24, 2025Phase 2 study in Primary Membranous NephropathyClimb Bio · NCT07096843 · 45 planned · United States, Argentina, Brazil and more
  8. Apr 27, 2026Phase 2 study in Systemic Lupus ErthematosusClimb Bio · NCT07564596 · 30 planned · China

Ahead

  1. Apr 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicClimb Bio · NCT07011043
  2. Aug 2027Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicClimb Bio · NCT07043946
  3. Sep 2027Primary completion: phase 2 study in Systemic Lupus ErthematosusClimb Bio · NCT07564596
  4. Oct 2027Primary completion: phase 2 study in Primary Membranous NephropathyClimb Bio · NCT07096843

TargetBeta

CD19 →read by rule
“Budoprutug is a humanized, immunoglobulin (Ig) G1 monoclonal antibody that selectively binds to CD19 and is projected to deplete targeted cells through antibody-dependent cellular cytotoxicity.”study text, by rule · the study

Other programs on CD19

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
inebilizumabruleAmgenphase 419
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
axicabtagene ciloleucelruleGilead Sciencesphase 310
surovatamigAstraZenecaphase 310
lisocabtagene maraleucelruleBristol-Myers Squibbphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
obexelimabzenas-biopharma-usa-llcphase 37
Autologous Anti-CD19 CAR-T Cells CABA-201rulecabaletta-biophase 36
zolacabtagene autoleucelBristol-Myers Squibbphase 36
Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753ruleGilead Sciencesphase 32
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07564596Systemic Lupus Erthematosus · China2RecruitingClimb BioSep 202730
NCT07096843Primary Membranous Nephropathy · United States, Argentina, Brazil and more2RecruitingClimb BioOct 202745
NCT07090655Healthy Volunteers · AustraliaEarly 1CompletedClimb BioApr 7, 202630
NCT07043946Purpura, Thrombocytopenic, Idiopathic · Bulgaria, Greece, Serbia and more2RecruitingClimb BioAug 202724
NCT07011043Lupus Erythematosus, Systemic · United States, Bulgaria, Georgia and more1RecruitingClimb BioApr 202730
NCT06570434Lupus Erythematosus, Systemic2WithdrawnTenet MedicinesDec 20260
NCT05441826Nephrosis, Lipoid · United States2TerminatedTenet MedicinesMay 3, 20231
NCT04652570Glomerulonephritis, Membranous · United States2TerminatedTenet MedicinesNov 21, 20236

How it is read

Names in the registry

  • “Budoprutug”, 4 entries
  • “budoprutug”, 2 entries
  • “VB119”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.